Polyrizon filed a divisional patent application with the European Patent Office to protect its proprietary Trap & Target intranasal drug delivery platform, following an earlier U.S. application covering both T&T and its Capture & Contain technology.

The T&T platform is designed to prolong API residence time at the nasal mucosa, enhance systemic bioavailability by bypassing first-pass metabolism, enable controlled release kinetics, prevent formulation dripping and utilize biodegradable polymers for a broad range of small molecules, peptides and antibodies.

This European filing complements Polyrizon’s existing U.S. patent coverage and underscores a strategic push to secure comprehensive intellectual property rights for its advanced intranasal hydrogel technologies, strengthening barriers to competition and potential licensing opportunities.

By targeting applications such as corticosteroids for allergic rhinitis, benzodiazepines for seizure control and naloxone for opioid overdose, the platform could open new market segments across respiratory, CNS and emergency treatment, supporting future clinical development and partnerships.